Akava announces IND clearance for AKV-9 to enter clinic for ALS
Aug. 23, 2023
Akava Therapeutics Inc. has announced FDA clearance of its IND application for AKV-9 (formerly NU-9) for the treatment of amyotrophic lateral sclerosis (ALS). The company is planning a first-in-human phase I study in healthy subjects.